Research
AstraZeneca Drug Becomes First Biologic to Cut COPD ‘Mucus Plugs,’ Data Show
At a major lung conference, AstraZeneca reported that its IL-33 inhibitor tozorakimab significantly reduced the airway-clogging mucus plugs that worsen COPD.